Zykadia Cap passes first wall of insurance benefit registration

A Novartis’s lung cancer therapy, Zykadia Cap(ceritinib) received a ‘insurance benefit adequacy’ evaluation as applied by a special case to be exempted in economic evaluation. It, thus, became the 5^th drug which passed the insurance benefit wall through the so-called ‘economic evaluation exemption.’

The Health Insurance Review & Assessment Service held the Drug Benefit Deliberation Committee o...